NCCN Guidelines Insights: Antiemesis, Version 2.2017

Authors: Michael J. Berger PharmD, BCOP1, David S. Ettinger MD1, Jonathan Aston PharmD, BCOP, BCPS1, Sally Barbour PharmD, BCOP1, Jason Bergsbaken PharmD, BCOP1, Philip J. Bierman MD1, Debra Brandt DO1, Dawn E. Dolan PharmD, BCOP1, Georgiana Ellis MD1, Eun Jeong Kim PharmD, MS1, Steve Kirkegaard PharmD1, Dwight D. Kloth PharmD, BCOP1, Ruth Lagman MD, MPH, MBA1, Dean Lim MD1, Charles Loprinzi MD1, Cynthia X. Ma MD, PhD1, Victoria Maurer MSN, OCN, RN1, Laura Boehnke Michaud PharmD, BCOP1, Lisle M. Nabell MD1, Kim Noonan MS, ANP, AOCN, RN1, Eric Roeland MD1, Hope S. Rugo MD1, Lee S. Schwartzberg MD1, Bridget Scullion PharmD, BCOP1, John Timoney PharmD, BCOP1, Barbara Todaro PharmD1, Susan G. Urba MD1, Dorothy A. Shead MS1, and Miranda Hughes PhD1
View More View Less
  • 1 From The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt-Ingram Cancer Center; Duke Cancer Institute; University of Wisconsin Carbone Cancer Center; Fred & Pamela Buffett Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Moffitt Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; Fox Chase Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; City of Hope Comprehensive Cancer Center; Mayo Clinic Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; UC San Diego Moores Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Memorial Sloan Kettering Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; and National Comprehensive Cancer Network.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 243 KB)
All Time Past Year Past 30 Days
Abstract Views 7 0 0
Full Text Views 30629 8982 806
PDF Downloads 15210 7050 640
EPUB Downloads 0 0 0